Must-attend session on October 6 in Milan, at the upcoming 44th Congress of the Italian Society of Invasive Cardiology - GISE, dedicated to the best interventional cardiology manuscripts from Italy, chaired by Giuseppe Tarantini and Carlo Di Mario! https://t.co/KzWk4XYv66

#CHIP session @ #euroctogisecto2023 2 complex #HRPCI LIB cases 📍you need to anticipate the risk of hemodynamic compromise and #pMCS use 📍#imaging MUST guide procedure 📍different available #debulking strategies according to pt @CtoEuro @sicigise

👩‍👩‍👧‍👧 #Cardiogenicshock in #women: discover our Editorial  https://t.co/6rA0vrCflZ 👉 how to fill the sex related gap in diagnostic and therapeutic management of CS? @G_Tarantini01 @alaide_chief @valeriaparadies @drbirgitvogel #InternationalJournalOfCardiology

Great to meet my friend and redo #TAVR guru @G_Tarantini01 #TVT2023! Finally after all these years!

Just out @JACCJournals #JACCINT our EXPLANTorREDO-TAVR registry on redo #TAVR vs explant #TAVR SVD/PVL/PPM. Ths 2 all collaborators! Nice @G_Tarantini01 editorial https://t.co/k3pOHLmUV5 @J_Sathananthan @SachinGoelMD @ShinFukuharaMD @KendraGrubb @drnvanmieghem @bapat_savrtavr

@NimeshDesaiMD @BaselRamlawiMD @tnazifMD @modine_thomas @TsuyoshiKaneko1 @m_taramasso @ArnarGeirssonMD @ronwaksman @johngraydonwebb @DrMoritzWvB @OKhaliqueMD @JoaoLCavalcante @mirvatalasnag @tomcnguyen @igeorge1975 @OPreventzaMD @StevenYakubov @mirvatalasnag @esaadi

Editorial by @G_Tarantini01

Just out @JACCJournals @JACCINT our editorial @G_Tarantini01 @tommaso_fabris on EXPLANTorREDO-TAVR Registry & STS database Registry 🔎redo AV interventions 🎯Current evidence and perspective on redo aortic permutations https://t.co/vdSr6z2RWp

At 15 months, NACE and MACCE did not differ in the 2 study groups, whereas the risk of major or clinically relevant nonmajor bleeding remained lower with abbreviated compared with standard antiplatelet therapy' https://t.co/hfStSHuxsK

📣PROTECT-EU study 🇮🇹🇩🇪 🥇First patient enrolled in Padua! 🎯CCS, 3VD, EF<30% Surgical refusal HRPCI+preventive strategy! #IMPELLACP @alaide_chief @BURZOTTA_F @CristinaAuri17 @giuliamasiero3 @saia_francesco @espogiov @sicigise @DrLucaTesta @AGIKinterv @MoritzSeiffert

Our state-of-the-art on provisional Left Main stenting is out! @JACCJournals @drnvanmieghem @G_Tarantini01 @Drroxmehran @alaide_chief @CaoDavide @hildicksmithd @ajaykirtane @dukwoo_park @JoostDaemen Smits Peter Diletti Roberto Kandzari David Banning Adrian

Number look good showing the interest of the audience on this topic - Tks again to dr Mirvat for the great debate

Target first study design published - going to the conclusion of enrollment

You can also discuss this consensus on the diagnosis and management of severe CAD in #TAVI candidates during our #EIJonAir today with author @G_Tarantini01 and @mirvatalasnag ! 📺Tune in at 4:00 PM here on #CardioTwitter (or on Facebook)!

For TAVI Patients With CAD, Lifetime Management Is Key: EAPCI | https://t.co/e960EsDUS4

In this real-world, multicentre European study, the authors found that the SAPIEN 3 Ultra was associated with a lower rate of PVL compared to its predecessor (S3), a result that was maintained at 1 year. #EAPCI @saia_francesco @G_Tarantini01 @tambucor https://t.co/mp3WZtqcSm

My last painting - farewell abyss

@DeBrabandereK @G_Tarantini01 @EACTS @escardio Well it's a paper regarding TAVR and PCI. It is mentioned that CABG is the gold standard in SAVR patients...

Honored to be part of this work on CAD and #TAVR with @G_Tarantini01 @LarsSondergaard et al @EuroInterventio @PCRonline @KHERA_MD @lamelaspablo @bapat_savrtavr @modine_thomas @vonBardelebenRS @barbanti_marco @didier_tchetche @djc795 @AndreasRck2 @DLBHATTMD @SVRaoMD @SachinGoelMD

This clinical consensus statement proposes a rationale for the diagnostic evaluation and indications for percutaneous revascularisation of CAD in patients with severe aortic stenosis undergoing transcatheter treatment. #EAPCI @G_Tarantini01 https://t.co/3rUms56KYa